• HyperScribe T7 High Yield Cy3 RNA Labeling Kit

  2026-09-09

  The HyperScribe T7 High Yield Cy3 RNA Labeling Kit supports tunable fluorescent RNA probe synthesis for spatial and transcript-level assays. This article explains how Cy3-labeled probes can strengthen RNAi research by connecting delivery, localization, and biological readouts without overstating what fluorescence alone can prove.

• GI 254023X: Selective ADAM10 Inhibitor Guide

  2026-09-09

  GI 254023X is a selective ADAM10 inhibitor with reported nanomolar potency and more than 100-fold selectivity over ADAM17. Research data connect ADAM10 inhibition with Notch1 signaling modulation, endothelial barrier protection, and vascular integrity enhancement in mouse models.

• Tamsulosin: From Receptor Selectivity to Translation

  2026-09-08

  A translational framework for using Tamsulosin to connect α1A-receptor pharmacology with smooth muscle, ureteral stone, and postoperative urinary retention research.

• Ziprasidone Augmentation in Anxious Depression

  2026-09-08

  This post-hoc moderator analysis examined whether baseline anxious depression altered the antidepressant or anxiolytic response to ziprasidone added to escitalopram. Depression outcomes improved similarly across anxiety subgroups, while the apparent anxiety benefit associated with greater baseline anxiety was not clinically meaningful, emphasizing cautious interpretation of subgroup effects.

• Go 6983 in Blastoid Metabolism Research

  2026-09-07

  Explore how Go 6983, a pan-PKC inhibitor, can support hypothesis-driven studies of WDR36, glycolysis, and trophectoderm differentiation in blastoid models. This article translates a human developmental study into careful assay-design principles while separating evidence from future applications.

• Azilsartan: Causal Logic for RAS Neuroinflammation Assays

  2026-09-07

  Azilsartan (TAK-536) enables selective AT1 receptor perturbation in cardiovascular and neuroinflammation research. This article develops a causal assay framework for interpreting astrocyte–microglia RAS findings, with particular attention to controls, phenotype ambiguity, and translational limits.

• Sitagliptin phosphate monohydrate Workflows

  2026-09-05

  Build cleaner DPP-4 inhibition experiments by pairing Sitagliptin phosphate monohydrate with oral glucose, intestinal-stretch, and incretin readouts. The workflow separates classical incretin biology from the GLP-1-independent satiety mechanism revealed in recent obesity research.

• Partial BACE Inhibition and Synaptic Transmission

  2026-09-04

  Satir et al. used optical electrophysiology in cultured rat cortical neurons to test whether moderate BACE inhibition can lower amyloid beta secretion without impairing neuronal communication. The study found that amyloid beta reduction below 50% preserved synaptic transmission across three inhibitors, whereas stronger inhibition reduced both measures, supporting exposure strategies that separate target engagement from synaptic dysfunction.

• 2D and 3D Radiosensitizer Screening in Lung Cancer

  2026-09-04

  The 2025 Acta Oncologica study systematically compared DNA-PKcs, ATR, PARP, and IAP pathway inhibitors in conventional 2D and extracellular-matrix-supported 3D lung cancer models. Its findings show that 2D assays often identify the same radiosensitizers as 3D systems, while 3D cultures add information about matrix-dependent and cell-line-specific responses that can improve preclinical prioritization.

• Canagliflozin in Renal Mitochondrial Research

  2026-09-03

  Canagliflozin enables researchers to connect renal glucose reabsorption inhibition with proximal-tubule mitochondrial structure, bioenergetics, and kidney injury markers. This workflow-focused guide shows how to translate SGLT2 inhibition into reproducible cell and mouse assays while controlling for solvent, sex, glycemia, and respirometry variables.

• BIRB 796 (Doramapimod) Assay Guide

  2026-09-03

  A scenario-based guide to using BIRB 796 (Doramapimod), SKU A5639, in cell viability, apoptosis, cytokine, and p38 MAPK experiments. It connects biochemical selectivity with practical stock preparation, assay controls, interpretation limits, and evidence-aware vendor selection.

• Adipose-Neural Signaling in Cardiac Arrhythmia

  2026-09-02

  Fan et al. establish a stem cell-based coculture model showing how epicardial adipose tissue can communicate with sympathetic neurons and cardiomyocytes through a leptin–NPY/Y1R pathway. The findings connect adipose-derived signaling with NCX and CaMKII activity, while patient data support increased epicardial fat and leptin/NPY levels as clinically relevant correlates of atrial fibrillation.

• Deferoxamine Mesylate: Iron Redox Assay Guide

  2026-09-02

  Deferoxamine mesylate gives researchers a practical way to manipulate labile iron, oxidative injury, ferroptosis susceptibility, and hypoxia signaling in controlled models. This workflow-focused guide covers preparation, HIF-1α stabilization, tumor and tissue assays, experimental controls, and troubleshooting limits.

• Dextromethorphan hydrobromide Workflows

  2026-09-01

  Build more reproducible NMDA and excitotoxicity assays with a controlled workflow for Dextromethorphan hydrobromide. The guide connects electrophysiology, cell-based neuroprotection, and cerebral ischemia model design while showing how the reference study supports stronger assay validation—not a new claim about the compound’s target.

• VX-745 and the Logic of p38α Signal Control

  2026-09-01

  VX-745 is a selective p38α MAPK inhibitor for dissecting kinase activity, inflammatory cytokine output, and phosphorylation-state dynamics. This guide connects product biology with a recent structural study to improve assay interpretation across inflammation, multiple myeloma, and aging research.

8053 records 1/537 page Next 12345 下5页 Last page